Continuous Glucose Monitoring for Diabetes

This trial tests a new glucose monitoring system, the Eversense Gemini System, to evaluate its effectiveness in measuring blood sugar and its safety for people with diabetes. The goal is to compare its accuracy and safety with other glucose monitoring systems. It suits adults who have had diabetes for at least a year and have not experienced severe low blood sugar or diabetic emergencies recently. As an unphased trial, this study allows participants to contribute to the development of innovative diabetes technology.

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are currently receiving certain treatments like immunosuppressants, chemotherapy, or specific anticoagulants. It's best to discuss your medications with the trial team to see if they affect your eligibility.

Research shows that the Eversense Gemini System, used for continuous glucose monitoring in people with diabetes, is safe. Studies have found that users generally tolerate the system well, and it accurately tracks glucose levels for up to 180 days. Most users did not experience serious side effects. The system's approval in Europe further supports its safety. Overall, evidence suggests that the Eversense Gemini System is a safe choice for adults with diabetes to monitor their glucose levels.¹²³⁴⁵

The Eversense Gemini System is unique because it offers continuous glucose monitoring (CGM) for up to a year with just one device insertion, unlike traditional CGMs that typically require sensor changes every 7 to 14 days. This system utilizes a small sensor implanted under the skin, which communicates with a wearable transmitter to provide real-time glucose readings directly to a smartphone app. Researchers are excited about this treatment as it promises greater convenience and longer-term monitoring, potentially enhancing diabetes management by reducing the burden of frequent sensor replacements and offering more consistent data for better glucose control.

Research has shown that the Eversense Gemini System, used by participants in this trial, accurately checks glucose levels. One study found it successfully alerted users 96.6% of the time when glucose was too low (70 mg/dL) and 97.9% of the time when it was too high (180 mg/dL). This indicates it can reliably warn users about unsafe glucose levels. The same study found that 90% of the sensors functioned for a full year, suggesting the system is both effective and durable for managing diabetes.²⁶⁷⁸